Cryogenx, a startup from London is also emerging as a prominent player in the healthtech sector through its efforts towards preventing heat stroke. One of the products of the company is the CGX1, a portable body cooling device that provides quick relief to individuals experiencing heatstroke or any form of heat illness. Cryogenx has recently raised £800K, which is a good result for the company.
Image Source: Cryogenx
Cryogenx’s CGX1, an “Ice Bath in a Backpack”
CGX1 from Cryogenx is a patent-pending core body cooling device. It is called an “ice pack in a backpack,” and it offers to cool on-demand cooling. The device includes a powerful coolant placed in compact cylinders into an adhesive, thermally conductive pad placed on the patient’s torso. This replicates the use of ice water immersion properly lowering the body core temperature which is essential in the treatment of heat stroke.
Image Source: Tech Funding News
Founder’s Inspiration
Cryogenx was founded by Matt Anderson and the idea was developed when he was still pursuing his Industrial Design degree at Brunel University. Initially, it all began when Matt watched a documentary where a cameraman died from heat-related issues while filming in a remote area. This made him understand that quick and efficient cooling could help to save lives, especially in complex and/or hard-to-reach areas.
Impact on the Market
The CGX1 is ideally positioned for industries where heat-related illness is common: It can be used in defense, construction, energy, manufacturing, and fire services to name a few. To achieve this, Cryogenx targets to partner with companies and distributors so that it can provide technological assistance to as many personnel as possible.
Cryogenx’s CGX1 prioritizes safety during cooling procedures
The device scans the patient’s core body temperature periodically. If cooling gets out of hand, it regulates the amount of coolant to ensure the patient is not put through hypothermia. The adhesive pad is well-secured, and it is also easy to remove. It neither hinders the skin nor brings about any form of discomfort. One advantage for users is that they can stop cooling at any one time should the need arise. The rules give a clear line on how one is supposed to use the language appropriately. In the best-case scenario, a medical professional oversees the administration of CGX1. They can know how the patients are reacting and also change accordingly. Thus, CGX1 is an effective tool for life-saving cooling, and at the same time, it incorporates safety protocols as well.
Conclusion
Cryogenx received funding from the British Design Fund, other shareholders, angels, and U.S. based funds. Cryogenx’s goal with this funding is to expand commercialization and to undertake its first official production cycle. CGX1 designed and developed by Cryogenx is an essential step towards wiping out heat-related death. It means that through offering a mobile and lifesaving solution when it comes to cooling, they are contributing to the fight against heat immensely.
